The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment by harnessing the immune system to target and eliminate cancer cells.

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

China: A recent case-control observational study has raised concerns about developing proteinuria in patients undergoing ...

Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biotech company with a market capitalization of $631 ...

The following is a summary of “An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma,” ...